A few days ago, CanSino Biological Co., Ltd. issued an announcement that the joint prevention and control mechanism of the State Council will hold a press conference on February 19, 2022. At the meeting, it was announced that, with the approval of the joint prevention and control mechanism of the State Council, the National Health and Health Commission has begun to deploy new crowns Sequential booster immunization of the vaccine.
Previously, all target groups over 18 years old who have been vaccinated with Sinopharm Zhongsheng Beijing Company, Beijing Kexing Company, Sinopharm Zhongsheng Wuhan Company or the company’s adenovirus vector vaccine for 6 months One dose of homologous booster immunization, that is, boosting with the original vaccine. After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of inoculation with the above three inactivated vaccines can also choose Zhifeilong Kema’s recombinant protein vaccine or the company’s adenovirus vector vaccine for sequential booster immunization. For the target population, one of homologous booster immunization and sequential booster immunization can be selected. Whether it is homologous boosting or sequential boosting, it needs to be implemented in people over the age of 18 who have completed the full vaccination for 6 months.
Up to now, the company’s recombinant novel coronavirus vaccine (type 5 adenovirus vector) has obtained conditional marketing approval in China and emergency use authorization in many overseas countries. After the product is approved for sequential booster immunization, if the relevant state departments subsequently increase its procurement, it will have a certain positive impact on the performance of the listed company.
According to the data of Wisdom Buds, as of the latest date, CanSino Biological Co., Ltd. has nearly 80 patents in 126 countries/regions around the world. From the perspective of patent status, about 17% of the company’s patents are currently under review, and 43% are valid patents; from the perspective of patent types, nearly 87% of the company’s patents are invention patents. From the company’s patent innovation word cloud, the company’s current patent layout mainly focuses on adenovirus, fusion protein, immunogenicity and other related professional fields.